Orticumab: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 48: | Line 48: | ||
{{dictionary-stub1}} | {{dictionary-stub1}} | ||
{{No image}} | {{No image}} | ||
__NOINDEX__ | |||
Revision as of 21:28, 17 March 2025
| Orticumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | 1314241-10-5 |
| PubChem | |
| DrugBank | |
| ChemSpider | none |
| KEGG | |
Orticumab (INN) is a human monoclonal antibody that is used as an anti-inflammatory agent and binds to oxLDL. It acts as an immunomodulator.<ref>World Health Organization,
International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107, WHO Drug Information, 2012, Vol. 26(Issue: 2), Full text,</ref>
References
<references/>
| Monoclonals for bone, musculoskeletal, circulatory, and neurologic systems | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
This article is a monoclonal antibody–related stub. You can help WikiMD by expanding it!
